PT-141

Product Introduction：

PT-141, scientifically known as bremelanotide, is a synthetic peptide and melanocortin receptor agonist under investigation for its potential to address sexual dysfunction. It uniquely influences sexual arousal through central nervous system pathways rather than focusing on vascular mechanisms, distinguishing it from other treatments such as PDE5 inhibitors. PT-141 has gained approval for the management of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, demonstrating its clinical relevance. Requires reconstitution before use.

• How doesPT-141 work?

PT-141 primarily acts as a melanocortin receptor agonist, with highest affinity for the melanocortin 4 receptor (MC4R) and melanocortin 1 receptor (MC1R). Research suggests the following mechanisms:

1. Central Nervous System: PT-141 activates MC4R in specific brain regions, particularly the hypothalamus and brainstem areas involved in sexual response. This activation is thought to influence neural pathways related to sexual desire and arousal.

2. Neurotransmitter Modulation: Studies indicate that PT-141 may increase dopamine release in the medial preoptic area, a region crucial for sexual motivation.

3. Peripheral Effects: PT-141’s interaction with MC1R on melanocytes has been studied for potential effects on skin pigmentation.

• Research

1. HSDD in Premenopausal Women:

Multiple Phase III clinical trials have evaluated PT-141’s efficacy for HSDD.

Studies typically measured changes in sexual desire and related distress using validated scales like the Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO).

Research has examined various dosing regimens and administration methods.

2. Other Areas of Investigation:

Male Sexual Function: Some studies have explored potential effects on erectile function, though this is not an FDA-approved use.

Dermatology: Limited research has investigated PT-141’s influence on melanogenesis and potential applications in pigmentation disorders.

Cardiovascular Effects: Studies have examined PT-141’s impact on blood pressure and heart rate, primarily for safety monitoring.

• Side Effects

Nausea

Flushing

Headache

Focal hyperpigmentation, which is generally reversible upon discontinuation of the drug

• Summary

PT-141 (Bremelanotide) is a synthetic peptide that has been the subject of extensive clinical research, particularly in the field of female sexual health. It is approved use for HSDD in premenopausal women represents a significant development in this therapeutic area. Ongoing studies continue to explore its mechanisms of action, potential applications, and long-term safety profile.

• Resource

All products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. The statements made on this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease. Power Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Power Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act. All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption. Power Peptides Products are intended strictly for research purposes only. These products are not approved by the U.S. Food and Drug Administration (FDA) for human consumption or medical use. Under no circumstances should these peptides be used for any purpose other than research. By purchasing or using our peptides, you acknowledge and agree that you will use them solely in accordance with applicable laws and regulations and that you accept full responsibility for their use. Statements made on this website have not been evaluated by the USA Food and Drug Administration.